Answers are grounded in this paper and cite their sources.
Observational analysis shows rapid improvement in HLH symptoms in a patient with RSV infection, suggesting tocilizumab may be an effective treatment option.
Hemophagocytic lymphohistiocytosis (HLH) may be triggered by infections (mostly viral infections). HLH triggered by the evolving respiratory syncytial virus (RSV) is rare. HLH is characterized by excessive immune activation and is life‐threatening with high mortality. We show that tocilizumab led to a rapid clinical improvement in a multirefractory RSV‐induced HLH patient. Tocilizumab appears to be a promising therapeutic option and is well‐tolerated.
No takes yet. Share an insight, caveat, or question.
Boiten et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: